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Acute kidney injury (AKI) has remained a significant health care concern with high 
mortality rates for several decades. The overall mortality rate of AKI is estimated to range 
between 45-70% [1-7]. AKI may be observed in up to 5% of hospitalized patients, and a 
diagnosis of AKI increases the risk of mortality 5.5 to 6.5-fold as compared to a similarly ill 
patient without AKI [3, 8]. In addition, AKI is now recognized as a potential cause of 
chronic kidney disease (CKD), as a significant number of patients may require continued 
dialytic therapy [3, 5-15], or may show a decline of function following discharge [7, 10, 13, 
16]. Recent estimates indicate that up to 3% of the yearly incidence of End-Stage Renal 
Disease in North America may be attributable, at least in part, to AKI [7, 17].
AKI can be classified clinically based on the genesis of the disorder as pre-renal, renal or 
post-renal. Ischemia due to hypotension or sepsis is the most common cause of human AKI 
[18] associated with frank renal injury. The activation of factors associated with 
vasoconstriction represents an important component of the renal injury process [19, 20]. It 
stands to reason that potential treatment modalities targeting vascular function in the setting 
of AKI may positively impact the dismal mortality rates currently achieved by supportive 
care alone.
This brief review will summarize recent advances on the understanding of renal endothelial 
function in the setting of AKI. We will consider primary roles of the endothelium in 
maintaining vascular tone and in influencing inflammation during progression of ischemia 
injury and highlight pathways for which interventional therapies have been shown 
efficacious in pre-clinical studies. Finally, we will consider the possible connection between 
AKI and CKD as a continuum, and reflect on the concept that promotion of vascular 
regeneration may represent a means to improve long term function following AKI.
Hemodynamic changes
The hallmark feature of AKI is a reduction in GFR, which implies an underlying impairment 
in hemodynamic regulation [21-25]. Indeed, this disorder was originally termed 
“vasomotor” nephropathy [21] and was characterized by a sustained increase in renal 
vascular resistance (RVR) [19, 26-28].
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Renal hemodynamic responses have been studied in animal models in response to renal 
ischemia reperfusion injury. After release of renal artery occlusion, total renal blood flow 
(RBF) is restored to baseline levels within minutes followed by a subsequent decline in 
RBF, which takes place over several hours [29, 30] [31-33]. Methods that discriminate 
regional blood flow in the kidney, suggest that outer medullary RBF undergoes an earlier 
and more significant impairment relative to whole kidney RBF [32-35]. The outer medulla is 
normally hypoxic under physiological conditions, and sustained reductions in outer 
medullary flow are considered to exacerbate hypoxia and contribute to the more profound 
degree of morphological damage observed in this region [34, 36].
The increased RVR can be viewed as a vascular response to cellular events triggered by the 
initial ischemia. Increased RVR may manifest as the activation of vasoactive compounds, 
reactive oxygen species and/or inflammatory pathways which can affect perfusion. Renal 
endothelial cells may be the target or the culprit of these responses.
When viewed from a clinical perspective, an increase in RVR triggered during reperfusion 
may represent a critical shift in the pathophysiological process driving AKI, in which 
systemic complications initiating a reduction in perfusion activate renal-intrinsic responses 
sustaining reduced perfusion and fueling parenchymal tissue injury. Such a shift may 
represent what has been referred to as the extension phase of AKI by Molitoris and Sutton 
and has been suggested as promising clinical window for therapeutic intervention, since the 
restoration of blood flow at this time would mitigate subsequent hypoxic damage [37]. 
However, because a number of different factors influence RVR and their contribution may 
change during injury progression, some therapies may be only effective in early stages of 
injury may have reduced impact later in the injury process. In practice, the clinical window 
of interventional opportunity may be short, and missed due to a lack of accurate and timely 
assessment of GFR [38]. Therefore, the utility of potential novel therapies will require 
coordination with newer methods in biomarker discovery to more accurately assess the 
phases of AKI [39].
Mediators of vasoconstriction
No single factor is responsible for reduced RBF, however vasoconstriction, tubular 
congestion, edema and inflammation are all likely to contribute to the increased RVR 
following ischemia reperfusion, with vasoconstriction representing the most immediate of 
these responses.
Several factors have been proposed to modulate renal vascular tone following I/R. For 
example, evidence indicates impaired proximal Na reabsorption due to energy depletion 
activates tubuloglomerular feedback and adenosine-mediated vasoconstriction following I/R 
[40]. A host of other potential vasoconstrictors may be activated and contribute to reduced 
RBF following I/R injury, including the systemic activation of the sympathetic nervous 
system, renin-angiotensin II system, endothelin A, prostaglandins, and platelet activating 
factors. Several studies have been undertaken in which inhibition of these factors provides a 
partial preservation of RBF and/or GFR and diminishes the severity of AKI [41-52]. 
However, because vasoconstriction is mediated by a number of redundant pathways, the 
blockade of any single pathway is not likely to completely protect against injury. Moreover, 
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such studies are almost always conducted by administration of an antagonist near the time of 
experimentally-induced reperfusion, while studies are rarely conducted to determine if 
delayed administration can reverse the course of injury after GFR becomes compromised. In 
some cases when treatments are delayed, there is a reduced efficacy in ameliorating AKI 
[53] [54] [55].
Endothelial involvement
Significant evidence exists that altered renal endothelial function contributes to a reduction 
in RBF following I/R. Sutton et al., demonstrated that I/R injury in rats alters cytoskeletal 
organization of small arterioles and endothelial cells [19, 56, 57]. These alterations 
contribute to the breakdown of VE-cadherin-mediated intercellular adhesion and the 
integrity of the tight junctions of peritubular capillaries as evidenced by leakiness of high 
molecular weight dextrans (>300,000 Da) into the interstitial space [57]. It has been 
suggested that increased leakiness may compromise renal perfusion by compressing 
peritubular capillaries and exacerbating erythrocyte trapping [19, 23, 58, 59].
Alterations in EC function may influence vasodilation, coagulation cascades and/or 
inflammatory processes [19, 60, 61]. Endothelial dysfunction is characterized, in part, by an 
impaired dilator capacity, which is often attributed to reduced production of nitric oxide. 
NOS3, (endothelial NOS) is produced at high levels in endothelial cells, particularly in the 
renal medulla [62], where it preserves medullary blood flow in response to renal 
vasoconstrictors such as Ang II [63]. However, following renal injury, there is impaired 
endothelial NOS (NOS3) function, demonstrated by a loss of vasodilator responses to 
acetylcholine and bradykinin [64]. This reduction in normal endothelial function does not 
appear to be the result of reduced NOS3 protein levels, but may result from inhibition of 
enzyme activity since bradykinin failed to produce measurable levels of NO in post-
ischemic kidneys measured in real time by electrochemical methods [64].
A role for NOS3 in preservation of blood flow is suggested by the greater degree of renal 
damage that occurs in NOS3 knockout mice in response to endotoxin [65] or by studies in 
which inhibition of compensatory vasodilation in AKI with L-NAME or cyclooxygenase 
inhibitors, exacerbates the degree of renal injury in response to ischemia reperfusion[30]. 
Interestingly, renal autoregulatory responses are impaired for at least 7 days post-ischemia 
endothelial responses, well into the recovery phases when total RBF has returned to baseline 
levels, suggesting prolonged endothelial dysfunction continues despite an overall recovery 
response [66, 67] [68]. Such impaired responses have been suggested to prolong injury or 
predispose further damage, as evidence of fresh ischemic injury has been observed in 
biopsies from in AKI patients treated with hemodialysis during the recovery process. [69]
Impaired NOS3 activity may result from endothelial damage or from extrinsic free radical 
activity altering NO activity. Reactive oxygen species may influence the effects of 
vasocontrictors and vasodilators and lead to an increase in renal vascular resistance. 
Increased renal superoxide production augments renal vasoconstrictor responses particularly 
in the renal medulla. Superoxide promotes vasoconstriction and enhances the reactivity of 
Ang II in the renal cortex and medulla [70]. Oxidative stress in the kidney also enhances the 
Basile and Yoder Page 3
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
vasoconstrictor effects of adenosine [71]. Superoxide, by virtue of its known activity to 
convert NO to peroxynitrite, may block the normal homeostatic mechanism maintaining 
medullary perfusion and these responses may be normalized with the use of antioxidants 
[70].
Several studies with the goal of increasing/preserving renal NO activity have demonstrated 
protective effects in AKI. For example, administration of L-arginine, the NO donor 
molsidomine, or the eNOS cofactor tetrohydroboipterin can preserve renal vascular 
perfusion and attenuate AKI induced by I/R [72-78]. Pharmacological approaches to impact 
NOS3 signaling by administration of PDE5 inhibitors have also been shown to ameliorate 
the severity of I/R induced AKI in rats[79] [80] or in pigs following cardiopulmonary 
bypass surgery [81].
Using videomicroscopy of blood vessels in the kidney, Yamamoto et al., reported that renal 
perfusion in peritubular vessels was compromised within minutes of unclamping, 
characterized by sluggish and occasionally retrograde blood flow [61]. Infusion of human 
umbilical vein endothelial cells to athymic nude rats, or other non-endothelial cells 
harboring the NOS3 gene expression construct, protected against this early compromise in 
blood flow [60]. Similar results were observed in endothelial-like cells were generated from 
mesenchymal cells in vitro and administered to rats in the setting of renal I/R [82]. Taken 
together, these data suggest that endothelial function, particularly via NOS3 activity, has 
protective effects on the severity of AKI.
While vasoconstriction contributes to the initial loss of GFR, it remains unclear whether 
therapeutic targeting can be used effectively to treat AKI, in part because tissue injury, once 
established, prevents vasodilatory therapy to generate desired effects. Perhaps the most well-
documented example of this principle is represented by the use of “renal-dose” dopamine. 
At low doses (i.e., 3 μg/kg/min) dopamine is vasodilatory and promotes diuresis primarily 
through the D-1 receptor and has protective effects in preclinical models of AKI [83]. 
Despite this, multiple studies have consistently demonstrated that renal-dose dopamine or 
the dopamine agonist fenoldapam, do not influence outcome of AKI in patients despite 
producing diuresis [84-88].
Endothelial cell involvement in inflammation
Despite some uncertainty about the role of specific leukocyte populations in human AKI, an 
infiltration of leukocytes, primarily neutrophils occurs fairly rapidly following ischemia/
reperfusion injury in rodents [89-91]. For more thorough discussion on the role of 
inflammation in AKI, the reader is referred to other articles on this topic [92, 93]. Leukocyte 
adhesion to activated endothelial cells following I/R may exacerbate injury by contributing 
to peritubular capillary congestion, by producing molecules that affect vascular tone (e.g., 
ROS or vasoactive lipids), or by liberating cytokines which contribute to parenchymal cell 
injury [36, 92].
Reductions in medullary blood flow occur prior to changes in total RBF. Whether leukocyte 
adhesion is associated with this decreased MBF in unclear since there have been no studies 
attempting to correlate medullary leukocyte adhesion and medullary perfusion. Despite this, 
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we advocate the proposed view that leukocyte adhesion represents a critical step in the 
switch to the extension phase of AKI and therefore may partially explain why vasodilator 
therapies alone are ineffective in established AKI. For this reason, there has been increased 
interest in understanding endothelial/leukocyte interactions and their potential targeting to 
mitigate the severity of I/R induced AKI.
There is an increase surface expression of the leukocyte adhesion molecules ICAM-1 and P 
and E-selectin on endothelial cells in response to injury [94-96]. In vivo imaging studies 
have shown leukocyte adhesiveness to the peritubular capillary wall occurs within hours of 
reperfusion [97, 98]. The endothelium may also be the source of chemoattractant factors, 
such as fractalkine (CX3CL1), which is expressed following renal injury and may promote 
infiltration of macrophages.
Treatments geared toward reducing endothelial/leukocyte interactions by targeting these 
endothelial adhesion molecules preserve blood flow and protect against renal damage in I/R 
induced AKI [94-96]. Blocking P selectin increases renal blood flow following I/R [29]. A 
landmark study in this area was published by Kelly et al., demonstrating that inhibition of 
ICAM or genetic deletion of ICAM resulted in a significant protection of ischemia 
reperfusion injury [99]. In human AKI, ICAM antibody pretreatment protected against 
delayed graft function in transplant recipients, relative to a group of recipients receiving the 
contralateral kidneys from the same donors. Interestingly, immunoneutralization following 
transplant did not affect the development of DGF [100-102].
Microthrombus formation has been described in renal I/R as well as in transplant 
biopsies[19, 103]. Although these pathways have not received prominent attention, the 
activation of prothrombotic events by activated endothelial cells represents a potentially 
important step in I/R injury. For example, tissue factor, a membranous glycoprotein that 
functions as a receptor for the coagulation system and is normally not present on quiescent 
endothelial cells, is expressed on peritubular capillary endothelial cells following renal I/R 
injury. Inhibition of endothelial tissue factor expression in rats following I/R injury results in 
significant improvement in mortality and preservation of overall morphology [104]. In 
addition, there is evidence that thrombomodulin, a thrombin inhibitor, is reduced on the 
surface of endothelial cells following renal ischemia reperfusion [19]. It was recently shown 
that administration of soluble thrombomodulin inhibitor to rats attenuated I/R induced AKI 
by preserving perfusion within renal capillaries and inhibiting leukocyte adhesion [98].
Additional therapies with potential anti thrombotic activity have received consideration in 
the setting of acute kidney injury. For example, activated protein C binds to receptors on the 
surface of endothelial cells where is has antithrombotic and direct cytoprotective effects on 
endothelial cells mediated by the protease activated receptor-1 (PAR-1) [105]. In a model of 
kidney ischemia reperfusion injury, APC administration preserved renal blood flow and 
protected against renal damage and inflammation [105].
It has been suggested that low protein C levels may predict morality in sepsis induced AKI. 
Administration of APC to septic rats improves renal function and lowers mortality. In a 
clinical trial of human sepsis patients, Drotrecogin (a recombinant human activated protein 
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C) significantly decreased 28 d mortality over the placebo group [106]. However, a more 
recent study of sepsis patients, recombinant APC provided no significant difference in 
mortality at 28 or 90 days [107]. Whether APC might provide beneficial effects in AKI in 
settings other than sepsis has not been evaluated.
Regeneration
The kidney is well known for its impressive regenerative capacity. In patients surviving 
AKI, recovery of renal function is generally expected. In many patients, recovery may not 
be complete, while some patients may develop chronic renal insufficiency and/or become 
susceptible to future episodes of AKI [10, 36]. The processes of renal repair and recovery 
after I/R injury have been studied extensively in animal models. In most studies, GFR and 
RBF return to basal levels rapidly (i.e., within days), while repair of damaged proximal 
tubules leads to the restoration of renal histological structure over several weeks. Despite 
this, even in otherwise healthy animals, there are persistent alterations in renal structure and 
function, and post AKI animals become predisposed to chronic disease.
Several theories have been proposed to describe the mechanisms by which predisposition to 
CKD may ensue following I/R injury [36, 108-111]. One possible mechanism relates to the 
reduction in peritubular capillary density that persists following the otherwise uneventful 
recovery from AKI [112]. Our laboratory demonstrated that there was a 30-50% reduction 
of PTC density which was present following the resolution of GFR, RBF and tubular 
morphology, at 4 weeks post I/R in rats [112, 113]. Similar results have been reported in 
other species such as mice [114], and in human kidneys following recovery from delayed 
graft function [115, 116].
The potential functional relationship between peritubular capillary loss and progressive 
fibrosis following I/R injury has been summarized in previous reviews [117-119]. In 
general, 3 possible mechanisms may contribute to the progressive development of renal 
fibrosis following injury, these include: 1) the exacerbation of hypoxia as a well-known 
physiological trigger promoting renal fibrosis [113], 2) an alteration in renal hemodynamic 
control, particularly in the renal medulla, which accentuates salt-sensitive hypertension and 
fuels progression of CKD [120, 121], and 3) the proliferation of new fibroblasts secondary 
to endothelial-mesenchymal transition [122]. As described below, treatments which 
ameliorate capillary loss post AKI reduce the development of secondary CKD [123]. 
Therefore strategies to preserve or restore renal vascular structure following injury represent 
an important potential area for therapeutic development.
The cellular basis of PTC rarefaction is incompletely understood. It is reasonable to suggest 
that apoptotic cell death underlies vascular (i.e., endothelial) cell loss following the 
induction of acute injury. Lee et al., demonstrated peritubular capillary endothelial cell 
apoptosis following severe liver I/R in mice which results in a subsequent AKI [124]. 
Recent studies have also reported apoptotic cells following acute injury in the region of the 
peritubular vasculature, but positive identification that EC are primarily affected is not clear 
[125]. In contrast, Hörbelt et al., used Tie-GFP mice to label renal endothelial cells and were 
not able to identify apoptotic endothelial cells in response to renal ischemia reperfusion, but 
did identify apoptotic endothelial cells in response to CD95 ligand infusion [114]. 
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Therefore, it is not clear whether apoptosis represents a prominent modality for the 
reduction of kidney endothelial cells post AKI.
We recently proposed an alternative mechanism for PTC rarefaction in which endothelial 
cells loss is manifested by a phenotypic transition via endothelial-mesenchymal transition 
(i.e., EndoMT). This suggestion is based on the co-localization of endothelial markers 
(CD31 or cablin) with mesenchymal markers (S100A4) as early as 6 hours and for up to 7 
days post AKI. Moreover, fate tracing studies using Cre-Lox targeting of EC, indicated that 
a population of interstitial cells present at 2 weeks post I/R may have derived from the 
endothelium [122].
Impaired mechanisms of capillary regeneration
Regardless of the mechanisms of dropout, PTC rarefaction post-AKI appears to be 
permanent [112] suggesting that the intrinsic regenerative capacity of renal capillaries is 
profoundly limited. This impaired regenerative response may stem in part from a lack of 
trophic support following AKI. In general, there is shift in the balance of paracrine factors 
toward an environment which likely inhibits endothelial stability [36, 117]. For example, 
TGF-beta is prominently but transiently induced post-AKI[126]. TGF-beta is a negative 
regulator of endothelial proliferation and may induce endoMT. Inhibition of TGF beta by 
administration of neutralizing antibodies to rats post AKI for 5 weeks preserved vascular 
density and attenuated the deposition of peritubular fibroblasts [127]. In addition, other 
inhibitors of endothelial cell growth are expressed following AKI including angiostatin, 
sFLT, ADAMTS-1, endostatin, arrestin and canstatin [114, 128, 129].
Renal tubular expression of VEGF is thought to be the primary source of local vascular 
trophic support, and the loss of this trophic activity may also shift the balance to impaired 
recovery. Despite hypoxia post AKI, there is no increase, and in some reports, a reduction in 
VEGF expression following AKI [129, 130]. Interestingly, other models of CKD are also 
characterized by a counter-intuitive reduction of VEGF expression which persists with the 
loss of peritubular and/or glomerular vessels [119, 131].
In contrast to CKD models, the reduction in VEGF expression is transient post-AKI, while 
the loss of vessels is permanent. We investigated whether the transient reduction in VEGF 
expression may influence vascular dropout. Exogenous VEGF-121 attenuated PTC 
rarefaction only when administration was initiated within the first few days of ischemia 
[123], but not when provided at a later time point, suggesting that replenishment of trophic 
support is only efficacious within a critical window of time during recovery.
In recent years, the question of how to replenish renal capillaries has received increased 
interest. The literature contains various examples of treatments that preserve renal PTC loss 
in response to injury using treatments such as VEGF infusion [123, 132, 133], comp-
angiopoiten-1 [134] or ramapril [135]. However, delayed administration of VEGF does not 
restore lost vessels [123, 136]. To the best of our knowledge, there have no reports in 
rodents have shown that renal vascular loss can be reversed once it has been firmly 
established. It may be interesting to note that at least one study using a swine model of renal 
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artery stenosis has demonstrated improvement of vascular structure with VEGF treatment 
[137].
Because endogenous renal expression of pro- and anti-angiogenic are restored to basal levels 
following recovery from AKI without evidence of vascular repair, and delayed VEGF 
administration has no apparent effect on capillary regeneration, we propose that sustained 
reduction in peritubular capillary density is the result of impaired growth responsiveness by 
the resident kidney endothelial cells. Indeed, there is a paucity of studies indicating that 
resident kidney endothelial cells have significant proliferative potential following 
completion of embryonic development [138]. Although a small number of studies using 
disease models such as diabetes and immune complex disease have reported evidence for 
capillary sprouting and endothelial cell proliferation in the glomerulus [139-143], most 
studies indicate peritubular capillary (PTC) endothelial cell proliferation is minimal in 
response to injury. Hoenstein et al., demonstrated a small degree of PTC endothelial 
proliferation in response to an antibody-mediated injury. The proliferative response was 
enhanced by erythropoietin, but erythropoietin did not provide a sustained benefit on PTC 
density [144]. In a recent study by our group, BrdU was dosed over a 7-day period to 
maximize detection of proliferating cells; we observed that PTC-EC proliferation was an 
extremely rare event following I/R; no BrdU positive endothelial cells were detected within 
2 days of I/R, while fewer than 1% of BrdU cells were endothelial after 7 days of continuous 
administration post I/R [145]. The administration of VEGF-121 preserved PTC density post 
AKI, but it did not increase the number of BrdU-positive ECs [145] suggesting that VEGF-
mediated protection of the renal vasculature occurs via a non-proliferative mechanism.
It is possible that a small degree of EC proliferation may mediate vascular repair responses 
in the injured kidney. Interestingly, Lin et al, have posited that capillary rarefaction may be 
mediated by a loss of the critical interaction of the endothelial cells with their neighboring 
pericytes in response to injury [146]. Renal derived pericytes stabilize human umbilical vein 
ECs in in vitro co-culture assays, but pericytes which have been activated by injury lose this 
stabilizing feature. The molecular pathways of this stabilizing effect have yet to be 
elucidated but may relate to the expression of TIMPs or ADAMTS-1 [147]. These studies 
suggest that if endothelial cell proliferation might be sufficient to induce a repair, activated 
renal pericytes may contribute to an environment incapable of maintaining repaired vessels. 
A better elucidation of these events will likely represent an important component in an 
overall strategy to revascularize the kidney.
Intrinsic and extrinsic endothelial progenitor cells in the kidney
There has been considerable interest in the role and the potential utility of endothelial 
progenitor cells (EPCs) in the setting of renal injury. The term endothelial progenitor cell 
was originally coined in a manuscript by Asahara et al., when a population of cells isolated 
from blood appeared to incorporate into sites of active angiogenesis [148]. EPCs are isolated 
when either low-density MNCs or isolated CD34+ or CD133+ enriched cells are plated on 
fibronectin-coated tissue culture surfaces, allowing distinct adherent colonies emerge after 
5–9 days. These are referred to as colony-forming unit-Hill (CFU-Hill) endothelial colonies, 
which express cell surface antigens CD31, CD105, CD144, CD146, vWF and KDR [149]. 
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However, it is increasingly recognized that these cells do not represent true EPCs, since they 
are rarely found in the endothelial layer of a repaired vessel [150-152]. In addition, these 
cells express markers of hematopoetic origin that are not present on endothelial cells, such 
as CD45. Therefore, they have more recently been referred to as “angiogenic macrophages”, 
“pro-angiogenic hematopoietic stem/progenitor cells” or proangiogenic cells (PAC) [151, 
152].
In kidney, understanding of PAC activity has been facilitated by studies in which labeled 
BM-derived cells have been found in the glomerulus following Thy 1.1 injury [153] or in 
the peritubular capillaries following adriamycin [154] or ischemic injury [155]. These 
studies report that these BM-derived cells differentiate into renal ECs on the basis of their 
expression of “endothelial” markers. However, it is well known that the expression of 
surface endothelial markers in bone marrow cells is not sufficient to define ECs [156]. 
Moreover, in a study by Li et al [154], BM-derived cells expressing endothelial markers 
peak within 14 days and decline by 28 days in kidney following adriamycin injury. Such a 
result is consistent with the transient homing of PACs to support local vascular remodeling, 
rather than stable incorporation and differentiation into more long-lived vascular endothelial 
cells. Despite significant interest in elucidating the trafficking of PACs to injured kidney, 
rarefaction of both glomerular and peritubular capillaries remains a prominent feature of 
these models, indicating that the endogenous activity of these cells is not sufficient to 
preserve or restore renal vascular injury.
Exogenous supplementation of PACs has shown great promise for multiple therapeutic 
applications by providing an enriched paracrine environment suitable for angiogenic/repair 
activity [157-160]. Within the kidney, studies from Goligorsky's group have shown that 
bone marrow derived PACs protect the loss of function following ischemia or adriamycin 
induced injury, by influencing hemodynamic or anti-inflammatory processes [150, 161, 
162]. Strategies which increase the activity or mobilization of pro-angiogenic bone marrow 
derived cells increase these protective effects [150, 161, 162]. In one study, the early 
administration of BM-PAC reduced the degree of PTC rarefaction following adriamycin- 
induced injury [161]. However, this study did not evaluate whether PACs were stably 
incorporated into PTCs. In addition, to the best of our knowledge, no studies in rodent 
models of acute injury have evaluated if PACs might restore PTC after rarefaction.
A second type of EPC has been described by Yoder and colleagues that can be isolated from 
peripheral blood and are not of hematopoietic origin. These cells are referred to as 
endothelial colony forming cells (ECFCs); they are clonally distinct from PACs and they 
have robust proliferative potential. ECFCs can form perfused vessels in vivo through a 
process of de novo vasculogenesis, while PACs do not display this activity [151]. ECFCs 
have also been shown to incorporate into and stimulate neovascularization in a hindlimb 
ischemia model [163].
A novel hypothesis has been proposed by Ingram et al., regarding cooperative interaction of 
ECFCs and BM-derived PACs in vascular repair/vasculogenesis [164]. Simply stated, it is 
suggested that hematopoietic cells (BM-PACs) home to sites of injury/remodeling to create 
a pro-angiogenic environment. The secretion of paracrine factors by BM-PACs recruits 
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ECFCs from either the circulation or the local vascular wall. Migration and proliferation of 
ECFCs are guided by BM-PAC activity leading to vascular repair and/or angiogenesis [164] 
In support of this hypothesis, when cultured in Matrigel plugs, these two cell types rapidly 
form capillary-like structures where the ECFC form the lumenized structures and the BM-
PACs migrate into the lumen of the formed vessels. In addition, co-adoptive transfer of both 
cell types has resulted in superior in vivo neo-angiogenesis when compared to a single cell 
transfers alone [165].
The isolation of ECFC illustrates that there is a hierarchy of ECFC proliferative potential 
which can be assessed by single-cell colony forming assays. Some ECFCs form large 
colonies (>10,000 over two weeks), which are referred to as high proliferative potential 
(HPP-ECFCs) and are enriched in human cord blood. ECFC are reduced in the blood of 
patients characterized by high cardiovascular risk status. ECFCs can also be isolated from 
the vessel walls of a variety of tissue sources in multiple species. This has led to the 
suggestion that the source of ECFC resides within the local vasculature [166].
We attempted to isolate rat kidney endothelial cells (KEC) and attempted to identify ECFC 
content within the isolated KEC. Consistent with reports from other investigators, kidney 
ECs proved difficult to maintain in long-term culture without transformation into 
mesenchymal cells. Compared to other EC cell types under optimal culture conditions, KEC 
displayed extremely slow growth kinetics. No ECFCs were identified when KEC were 
plated at a clonal level which were capable of forming large colonies (i.e., > 2000 cells/2 
weeks). Moreover, rat kidney ECs failed to proliferate in response to VEGF addition to the 
culture media, despite showing prominent expression of numerous VEGF receptors. These 
cells do not express markers typical of senescence and we propose that these cells may be 
growth restricted by a post-receptor signaling pathway [167].
In consideration of how kidney endothelial cell growth potential and PACs may operate in 
vascular repair, we recall that the paradigm outlined by Ingram et al., indicates that that 
vascular repair mediated by PACs is contingent upon the activation of a local ECFC, 
capable of participating in repair. Based on the fairly-common observation that PTC 
capillaries lack regenerative potential we hypothesize that limited renal ECFC potential is 
the basis for persistent vascular loss despite the apparent deposition of a population of cells 
that would be classified as PACs following injury.
We propose that future studies seek to determine whether proliferation competent ECFCs 
and PACs may work to minimize vascular rarefaction and/or regenerate renal vessels post 
rarefaction. Since rodents have no circulating ECFCs, studies will have to determine how 
adoptive transfer of competent ECFCs may occur and home to the kidney to work with 
PAC. In contrast, larger animals, including humans, may have a circulating ECFC 
population but may require strategies to target these to the kidney and participate in repair. 
Regardless, since PTC rarefaction is a feature of nearly all forms of CKD, it will be 
important to further investigate potential therapies seeking to revascularize the kidney.
Summary—Impaired endothelial function plays a central role in the pathogenesis of acute 
kidney injury. The potential to treat endothelial dysfunction and alter the course of acute 
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kidney injury requires an understanding of the fundamental processes of injury an 
progression in response to ischemia. Figure 1 summarizes how alterations in endothelial 
function may relate the pathogenesis of acute kidney injury. During the initiation phase, 
vasodilator therapies may by effective in animal models, however the lack of efficacy in 
clinical trials may relate to fact that AKI diagnosis is delayed until at least the extension 
phase, when alterations in endothelial leukocyte interactions may be a prominent activity. 
Long term alterations may relate to peritubular capillary loss, which can be preserved by 
experimental treatments during the early phases of injury and repair, but ultimately become 
refractory to pro-angiogenic therapies.
Acknowledgments
DPB and MY are supported by NIH grant DK063114.
Citations
1. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and Outcomes of 
Acute Renal Failure in Hospitalized Patients: A National Survey. Clinical Journal of the American 
Society of Nephrology. 2006; 1(1):43–51. [PubMed: 17699189] 
2. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, Godinez-Luna T, Svenson 
LW, Rosenal T. Prognosis for long-term survival and renal recovery in critically ill patients with 
severe acute renal failure: a population-based study. Crit Care. 2005; 9(6):R700–9. [PubMed: 
16280066] 
3. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. 
JAMA. 1996; 275(19):1489–94. [PubMed: 8622223] 
4. Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change? J Am 
Soc Nephrol. 2003; 14(8):2178–87. [PubMed: 12874474] 
5. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002; 39(5):
930–6. [PubMed: 11979336] 
6. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, 
Macedo E, Gibney N, Tolwani A, Ronco C. Acute renal failure in critically ill patients: a 
multinational, multicenter study. JAMA. 2005; 294(7):813–8. [PubMed: 16106006] 
7. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG. Chronic dialysis and death 
among survivors of acute kidney injury requiring dialysis. JAMA. 2009; 302(11):1179–85. 
[PubMed: 19755696] 
8. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute Kidney Injury, Mortality, 
Length of Stay, and Costs in Hospitalized Patients. Journal of the American Society of Nephrology. 
2005; 6(11):3365–3370. [PubMed: 16177006] 
9. Chertow GM, Christiansen CL, Cleary PD, Munro C, Lazarus JM. Prognostic stratification in 
critically ill patients with acute renal failure requiring dialysis. Arch Intern Med. 1995; 155(14):
1505–11. [PubMed: 7605152] 
10. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ. Acute kidney 
injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009; 20(1):223–8. [PubMed: 
19020007] 
11. Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the 
intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure 
Study Group. Kidney Int Suppl. 1998; 66:S16–24. [PubMed: 9580541] 
12. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-
based study. Madrid Acute Renal Failure Study Group. Kidney Int. 1996; 50(3):811–8. [PubMed: 
8872955] 
Basile and Yoder Page 11
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
13. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordonez JD, Hsu CY. Dialysis-requiring 
acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009; 
76(8):893–9. [PubMed: 19641480] 
14. Morgera S, Kraft AK, Siebert G, Luft FC, Neumayer HH. Long-term outcomes in acute renal 
failure patients treated with continuous renal replacement therapies. Am J Kidney Dis. 2002; 
40(2):275–9. [PubMed: 12148099] 
15. Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a 
prospective study in critically ill patients. Nephrol Dial Transplant. 2006; 21(5):1248–52. 
[PubMed: 16449291] 
16. Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of 
acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int. 2009; 76(10):
1089–97. [PubMed: 19741590] 
17. Waikar SS, Winkelmayer WC. Chronic on acute renal failure: long-term implications of severe 
acute kidney injury. JAMA. 2009; 302(11):1227–9. [PubMed: 19755705] 
18. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. 
Incidence and mortality of acute renal failure in medicare beneficiaries, 1992 to 2001. J Am Soc 
Nephrol. 2006; 17:1135–1142. [PubMed: 16495381] 
19. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during 
ischemic acute renal failure. Kidney International. 2002; 62(5):1539–49. [PubMed: 12371954] 
20. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal 
failure. J Am Soc Nephrol. 2003; 14:2199–2210. [PubMed: 12874476] 
21. Hollenberg NK, Epstein FH, Rosen S, Basch R, Oken D. Merrill, Acute oliguric renal failure in 
man: evidence for preferential renal cortical ischemia. Medicne (Balt). 1968; 47(6):455–74.
22. Karlberg L, Norlen BJ, Ojteg G, Wolgast M. Impaired medullary circulation in postischemic acute 
renal failure. Acta Physiologica Scandinavica. 1983; 118(1):11–7. [PubMed: 6624494] 
23. Hellberg POA, Kallskog OT, Ojteg G, Wolgast M. Peritubular capillary permeability and 
intravascular RBC aggregation after ischemia: effects of neutrophils. American Journal of 
Physiology. 1990; 258:F1018–F1025. Renal Fluid Electrolyte Physiology. [PubMed: 2330969] 
24. Mason J, Torhorst J, Welsch J. Role of the medullary perfusion defect in the pathogenesis of 
ischemic renal failure. Kidney Int. 1984; 26:283–293. [PubMed: 6513274] 
25. Dagher PC, Herget-Rosenthal S, Ruehm SG, Jo SK, Star RA, Agarwal R, Molitoris BA. Newly 
developed techniques to study and diagnose acute renal failure. Journal of the American Society of 
Nephrology. 2003; 14(8):2188–98. [PubMed: 12874475] 
26. Sheridan AM, Bonventre JV. Cell biology and molecular mechanisms of injury in ischemic acute 
renal failure. Current Opinion in Nephrology & Hypertension. 2000; 9(4):427–34. [PubMed: 
10926180] 
27. Park K, Chen A, Bonventre JV. Prevention of kidney ischemia/reperfusion induced functional 
injury and JNK, p38 and MAPK kinase activation by remote ischemic pretreatment. Journal of 
Biological Chemistry. 2001; 276(15):11870–6. [PubMed: 11150293] 
28. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal 
failure. Journal of the American Society of Nephrology. 2003; 14(8):2199–210. [PubMed: 
12874476] 
29. Bojakowski K, Abramczyk P, Bojakowska M, Zwolinska A, Przybylski J, Gaciong Z. Fucoidan 
improves the renal blood flow in the early stage of renal ischemia/reperfusion in the rat. Journal of 
Physiology and Pharmacology. 2001; 52(1):137–143. [PubMed: 11321507] 
30. Cristol JP, Thiemermann C, Mitchell JA, Walder C, Vane JR. Support of renal blood flow after 
ischaemic-reperfusion injury by endogenous formation of nitric oxide and of cyclo-oxygenase 
vasodilator metabolites. British Journal of Pharmacology. 1993; 109(1):188–194. [PubMed: 
7684301] 
31. Versteilen AMG, Korstjens IJM, Musters RJP, Groeneveld ABJ, Sipkema P. Rho kinase regulates 
renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney. American 
Journal of Physiology - Renal Physiology. 2006; 291(3):F606–F611. [PubMed: 16525157] 
Basile and Yoder Page 12
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
32. Regner KR, Zuk A, Van Why SK, Shames BD, Ryan RP, Falck JR, Manthati VL, McMullen ME, 
Ledbetter SR, Roman RJ. Protective effect of 20-HETE analogues in experimental renal ischemia 
reperfusion injury. Kidney Int. 2008; 75(5):511–517. [PubMed: 19052533] 
33. Shi H, Patschan D, Epstein T, Goligorsky MS, Winaver J. Delayed recovery of renal regional 
blood flow in diabetic mice subjected to acute ischemic kidney injury. American Journal of 
Physiology - Renal Physiology. 2007; 293(5):F1512–F1517. [PubMed: 17881464] 
34. Regner K, Roman R. Role of medullary blood flow in the pathogenesis of renal ischemia-
reperfusion injury. Current Opinion in Nephrology and Hypertension. 2012; 21(1):33–38. 
[PubMed: 22080855] 
35. Saito M, Miyagawa I. Real-time monitoring of nitric oxide in ischemia-reperfusion rat kidney. 
Urological Research. 2000; 28(2):141–146. [PubMed: 10850639] 
36. Basile DP, Anderson M, Sutton TA. Pathophysiology of acute kidney injury. Comprehensive 
Physiology. 2012; 2:1303–1353. [PubMed: 23798302] 
37. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute 
renal failure. Kidney International. 2004; 66(2):496–9. [PubMed: 15253696] 
38. Jo SK, Rosner MH, Okusa MD. Pharmacologic Treatment of Acute Kidney Injury: Why Drugs 
Haven't Worked and What Is on the Horizon. Clinical Journal of the American Society of 
Nephrology. 2007; 2(2):356–365. [PubMed: 17699435] 
39. Honore P, Jacobs R, Joannes-Boyau O, Verfaillie L, De Regt J, Van Gorp V, De Waele E, Boer W, 
Collin V, Spapen H. Biomarkers for early diagnosis of AKI in the ICU: ready for prime time use at 
the bedside? Annals of Intensive Care. 2012; 2(1):24. [PubMed: 22747706] 
40. Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney 
Int. 1984; 25(5):739–746. [PubMed: 6381854] 
41. Fujii T, Kurata H, Takaoka M, Muraoka T, Fujisawa Y, Shokoji T, Nishiyama A, Abe Y, 
Matsumura Y. The role of renal sympathetic nervous system in the pathogenesis of ischemic acute 
renal failure. European Journal of Pharmacology. 2003; 481(2-3):241–248. [PubMed: 14642792] 
42. Salman IM, Ameer OZ, Sattar MA, Abdullah NA, Yam MF, Najim HS, Khan AH, Johns EJ. Role 
of the renal sympathetic nervous system in mediating renal ischaemic injury-induced reductions in 
renal haemodynamic and excretory functions. Pathology. 42(3):259–266. [PubMed: 20350220] 
43. Wang W, Falk SA, Jittikanont S, Gengaro PE, Edelstein CL, Schrier RW. Protective effect of renal 
denervation on normotensive endotoxemia-induced acute renal failure in mice. American Journal 
of Physiology - Renal Physiology. 2002; 283(3):F583–F587. [PubMed: 12167611] 
44. Sreedharan, R.; Devarajan, P.; Van Why, S. Pathogenesis of acute renal failure. In. In: Avner, E.; 
Harmon, W.; Niaudet, P.; Yoshikawa, N., editors. Pediatric Nephrology. 6th. Springer-Verlag; 
Heidleberg: 2009. p. 1579-1602.
45. Nishiyama A, Miyatake A, Aki Y, Fukui T, Rahman M, Kimura S, Abe Y. Adenosine A1 Receptor 
Antagonist KW-3902 Prevents Hypoxia-Induced Renal Vasoconstriction. Journal of 
Pharmacology and Experimental Therapeutics. 1999; 291(3):988–993. [PubMed: 10565815] 
46. Wilhelm SM, Simonson MS, Robinson AV, Stowe NT, Schulak JA. Endothelin up-regulation and 
localization following renal ischemia and reperfusion. Kidney International. 1999; 55(3):1011–8. 
[PubMed: 10027938] 
47. Huang C, Huang C, Hestin D, Dent PC, Barclay P, Collis M, Johns EJ. The effect of endothelin 
antagonists on renal ischaemia-reperfusion injury and the development of acute renal failure in the 
rat. Nephrology Dialysis Transplantation. 2002; 17(9):1578–1585.
48. Knoll T, Schult S, Birck R, Braun C, Michel MS, Bross S, Juenemann KP, Kirchengast M, 
Rohmeiss P. Therapeutic administration of an endothelin-A receptor antagonist after acute 
ischemic renal failure dose-dependently improves recovery of renal function. Journal of 
Cardiovascular Pharmacology. 2001; 37:483–8. [PubMed: 11300661] 
49. Büyükgebiz O, Aktan AÖ, Haklar G, Yalçin AS, Yeğen C, Yalin R, Ercan ZS. BQ-123, a specific 
endothelin (ET1) receptor antagonist, prevents ischemia- reperfusion injury in kidney 
transplantation. Transplant International. 1996; 9(3):201–207. [PubMed: 8723187] 
50. Lopez-Novoa JM. Potential role of platelet activating factor in acute renal failure. Kidney Int. 
1999; 55(5):1672–1682. [PubMed: 10231429] 
Basile and Yoder Page 13
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
51. Wang W, Zolty E, Falk S, Summer S, Stearman R, Geraci M, Schrier R. Prostacyclin in 
endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin 
synthase transgenic mice. American Journal of Physiology – Renal Physiology. 2007; 
293(4):F1131–F1136. [PubMed: 17652370] 
52. Tobimatsu M, Euda Y, Saito S, Tsumagari T, Konomi K. Effects of a stable prostocyclin analog on 
experimental ischemic acute renal failure. Ann Surg. 1988; 208:65–70. [PubMed: 3291800] 
53. Vargas A, Krishnamurthi V, Masih R, Robinson A, Shchulak J. Prostaglandin E1 attenuation of 
ischemic renal reperfusion in the rat. J Am Coll Surg. 1995; 180:713–717. [PubMed: 7773485] 
54. Gellai M, Jugus M, Fletcher T, DeWolf R, Nambi P. Reversal of postischemic acute renal failure 
with a selective endothlin-A receptor antagonist. The Journal of Clinical Investigation. 1994; 
93:900–906. [PubMed: 8113422] 
55. Boffa JJ, Just A, Coffman TM, Arendshorst WJ. Thromboxane Receptor Mediates Renal 
Vasoconstriction and Contributes to Acute Renal Failure in Endotoxemic Mice. Journal of the 
American Society of Nephrology. 2004; 15(9):2358–2365. [PubMed: 15339984] 
56. Kwon O, Phillips CL, Molitoris BA. Ischemia induces alterations in actin filaments in renal 
vascular smooth muscle cells. American Journal of Physiology - Renal Fluid & Electrolyte 
Physiology. 2002; 282:F1012–9.
57. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, Molitoris BA. Injury of the renal 
microvascular endothelium alters barrier function after ischemia. American Journal of Physiology 
- Renal Physiology. 2003; 285(2):F191–8. [PubMed: 12684225] 
58. Hellberg PO, Kallskog O, Wolgast M. Nephron function in the early phase of ischemic renal 
failure. Significance of erythrocyte trapping. Kidney International. 1990; 38:432–9. [PubMed: 
2232485] 
59. Hellberg POA, Kallskog O, Wolgast M. Red cell trapping and postischemic renal blood flow. 
Differences between the cortex, outer and inner medulla. Kidney Int. 1991; 40:625–631. [PubMed: 
1745011] 
60. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, Goligorsky MS. Endothelial 
dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. American 
Journal of Physiology - Renal Fluid & Electrolyte Physiology. 2002; 282(6):F1140–9.
61. Yamamoto T, Tada T, Brodsky SV, Tanaka H, Noiri E, Kajiya F, Goligorsky MS. Intravital 
videomicroscopy of peritubular capillaries in renal ischemia. American Journal of Physiology - 
Renal Fluid & Electrolyte Physiology. 2002; 282(6):F1150–5.
62. Mattson DL, Lu S, Cowley AW Jr. Role of nitric oxide in the control of the renal medullary 
circulation. Clinical & Experimental Pharmacology & Physiology. 1997; 24(8):587–90. [PubMed: 
9269532] 
63. Zou AP, Wu F, Cowley AW Jr. Protective effect of angiotensin II-induced increase in nitric oxide 
in the renal medullary circulation. Hypertension. 1998; 31:271–6. [PubMed: 9453315] 
64. Conger JD, Robinette JB, Schrier RW. Smooth muscle calcium and endothelium derived relaxing 
factor in the abnormal vascular responses of acute renal failure. Journal of Clinical Investigation. 
1988; 82:532–537. [PubMed: 3261301] 
65. Wang W, Mitra A, Poole B, Falk S, Lucia MS, Tayal S, Schrier R. Endothelial nitric oxide 
synthase-deficient mice exhibit increased susceptibility to endotoxin-induced acute renal failure. 
American Journal of Physiology - Renal Physiology. 2004; 287(5):F1044–F1048. [PubMed: 
15475535] 
66. Conger JD, Schultz MF, Miller F, Robinette JB. Responses to hemorrhagic arterial pressure 
reduction in different ischemic renal failure models. Kidney International. 1994; 46(2):318–23. 
[PubMed: 7967342] 
67. Conger JD, Robinette JB, Villar A, Raij L, Shultz P. Increased nitric oxide synthase activity 
despite lack of response to endothelium-dependent vasodilators in post-ischemic acute renal 
failure in rats. Journal of Clinical Investigation. 1995; 96:631–638. [PubMed: 7542287] 
68. Adams PL, Adams FF, Bell PD, Navar LG. Impaired renal blood flow autoregulation in ischemic 
acute renal failure. Kidney Int. 1980; 18(1):68–76. [PubMed: 7218661] 
Basile and Yoder Page 14
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
69. Solez K, Morel-Maroger L, Sraer JD. The Morphology of “Acute Tubular Necrosis” in Man: 
Analysis of 57 Renal Biopsies and a Comparison with the Glycerol Model. Medicine. 1979; 58(5):
362–376. [PubMed: 481195] 
70. Zou AP, Li N, Cowley AW Jr. Production and actions of superoxide in the renal medulla. 
Hypertension. 2001; 37:547–53. [PubMed: 11230333] 
71. Chen YF, Li PL, Zou AP. Oxidative stress enhances the production and actions of adenosine in the 
kidney. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology. 
2001; 281(6):R1808–R1816.
72. Schneider R, Raff U, Vornberger N, Schmidt M, Freund R, Reber M, Schramm L, Gambaryan S, 
Wanner C, Schmidt HHHW, Galle J. L-Arginine counteracts nitric oxide deficiency and improves 
the recovery phase of ischemic acute renal failure in rats. Kidney Int. 2003; 64(1):216–225. 
[PubMed: 12787412] 
73. Garcia-Criado FJ, Eleno N, Santos-Benito F, Valdunciel JJ, Reverte M, Lozano-Sanchez FS, 
Ludena MD, Gomez-Alonso A, Lopez-Novoa JM. Protective effect of exogenous nitric oxide on 
the renal function and inflammatory response in a model of ischemia-reperfusion. Transplantation. 
1998; 66(8):982–90. [PubMed: 9808479] 
74. Dagher F, Pollina RM, Rogers DM, Gennaro M, Ascer E. The value and limitations of L-arginine 
infusion on glomerular and tubular function in the ischemic/reperfused kidney. Journal of Vascular 
Surgery. 1995; 21(3):453–8. [PubMed: 7877227] 
75. Schramm L, La M, Heidbreder E, Hecker M, Beckman JS, Lopau K, Zimmermann J, Rendl J, 
Reiners C, Winderl S, Wanner C, Schmidt HH. L-arginine deficiency and supplementation in 
experimental acute renal failure and in human kidney transplantation. Kidney International 2002. 
2002 Apr; 61(4):1423–32.
76. Schneider R, Raff U, Vornberger N, Schmidt M, Freund R, Reber M, Schramm L, Gambaryan S, 
Wanner C, Schmidt HH, Galle J. L-Arginine counteracts nitric oxide deficiency and improves the 
recovery phase of ischemic acute renal failure in rats. Kidney International. 2003; 64:216–25. 
[PubMed: 12787412] 
77. Kakoki M, Hirata Y, Hayakawa H, Suzuki E, Nagata D, Tojo A, Nishimatsu H, Nakanishi N, 
Hattori Y, Kikuchi K, Nagano T, Omata M. Effects of tetrahydrobiopterin on endothelial 
dysfunction in rats with ischemic acute renal failure. J Am Soc Nephrol. 2000; 11:301–309. 
[PubMed: 10665937] 
78. Sucher R, Gehwolf P, Oberhuber R, Hermann M, Margreiter C, Werner ER, Obrist P, 
Schneeberger S, Ollinger R, Margreiter R, Brandacher G. Tetrahydrobiopterin protects the kidney 
from ischemia-reperfusion injury. Kidney Int. 2010; 77(8):681–689. [PubMed: 20164829] 
79. Sohotnik R, Nativ O, Abbasi A, Awad H, Frajewicki V, Bishara B, Sukhotnik I, Armaly Z, 
Aronson D, Heyman SN, Nativ O, Abassi ZA. Phosphodiesterase5 Inhibition Attenuates Early 
Renal Ischemia/Reperfusion-Induced Acute Kidney Injury: Assessment by measurement of 
urinary NGAL and KIM-1. American Journal of Physiology - Renal Physiology. 2013
80. Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, Lee KW. 
Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. American Journal of 
Physiology - Renal Physiology. 2009; 297(2):F362–F370. [PubMed: 19474186] 
81. Patel NN, Lin H, Toth T, Jones C, Ray P, Welsh GI, Satchell SC, Sleeman P, Angelini GD, 
Murphy GJ. Phosphodiesterase-5 Inhibition Prevents Postcardiopulmonary Bypass Acute Kidney 
Injury in Swine. The Annals of Thoracic Surgery. 2012; 92(6):2168–2176. [PubMed: 21983073] 
82. Arriero M, Brodsky SV, Gealekman O, Lucas PA, Goligorsky MS. Adult skeletal muscle stem 
cells differentiate into endothelial lineage and ameliorate renal dysfunction after acute ischemia. 
American Journal of Physiology - Renal Physiology. 2004; 287(4):F621–7. [PubMed: 15198930] 
83. Denton Mark D, Chertow GM, Brady HR. [ldquo]Renal-dose[rdquo] dopamine for the treatment 
of acute renal failure: Scientific rationale, experimental studies and clinical trials. Kidney Int. 
1996; 50(1):4–14. [PubMed: 8807566] 
84. Kellum JA, M Decker J. Use of dopamine in acute renal faiulre: a meta analysis. Crit Care Med. 
2001; 29(8):1526–31. [PubMed: 11505120] 
85. Kellum JA. Systematic review: The use of diuretics and dopamine in acute renal failure: a 
systematic review of the evidence. Critical Care. 1997; 1(2):53–59. [PubMed: 11094464] 
Basile and Yoder Page 15
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
86. Bellomo R, Chapman M, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal 
dysfunction: a placebo-controlled randomised trial. The Lancet. 2000; 356(9248):2139–2143.
87. Lauschke A, Teichgraber UKM, Frei U, Eckardt KU. ‘Low-dose’ dopamine worsens renal 
perfusion in patients with acute renal failure. Kidney Int. 2006; 69(9):1669–1674. [PubMed: 
16572117] 
88. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam Mesylate in 
Early Acute Tubular Necrosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
American journal of kidney diseases : the official journal of the National Kidney Foundation. 
2005; 46(1):26–34. [PubMed: 15983954] 
89. Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, Kobayashi K, Mukaida N, Matsushima K, 
Yokoyama H. Administration of FR167653, a new anti-inflammatory compound, prevents renal 
ischaemia/reperfusion injury in mice. Nephrology Dialysis Transplantation. 2002; 17(3):399–407.
90. Miyazawa S, Watanabe H, Miyaji C, Hotta O, Abo T. Leukocyte accumulation and changes in 
extra-renal organs during renal ischemia reperfusion in mice. Journal of Laboratory and Clinical 
Medicine. 2002; 139(5):269–278. [PubMed: 12032487] 
91. Ysebaert DK, De Greef KE, Vercauteren SR, Ghielli M, Verpooten GA, Eyskens EJ, De Broe ME. 
Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. 
Nephrology Dialysis Transplantation. 2000; 15(10):1562–1574.
92. Kinsey GR, Li L, Okusa MD. Inflammation in Acute Kidney Injury. Nephron Experimental 
Nephrology. 2008; 109(4):e102–e107. [PubMed: 18802372] 
93. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int. 2004; 66(2):
486–491. [PubMed: 15253694] 
94. Molitoris BA, Sandoval R, Sutton TA. Endothelial injury and dysfunction in ischemic acute renal 
failure. Critical Care Medicine. 2002; 30(5 Suppl):S235–40. [PubMed: 12004242] 
95. Kelly KJ, Williams WW Jr, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects 
the kidney against ischemic injury. Proceedings of the National Academy of Sciences of the 
United States of America. 1994; 91(2):812–6. [PubMed: 7904759] 
96. Fuller TF, Sattler B, Binder L, Vetterlein F, Ringe B, Lorf T. Reduction of severe ischemia/
reperfusion injury in rat idney grafts by a soluble P-Selectin glycprotein ligand. Tranplantation. 
2001; 72:216–222.
97. Kelly KJ, Sutton TA, Weathered N, Ray N, Caldwell EJ, Plotkin Z, Dagher PC. Minocycline 
inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol. 2004; 
287:F760–F766.
98. Sharfuddin AA, Sandoval RM, Berg DT, McDougal GE, Campos SB, Phillips CL, Jones BE, 
Gupta A, Grinnell BW, Molitoris BA. Soluble Thrombomodulin Protects Ischemic Kidneys. 
Journal of the American Society of Nephrology. 2009; 20(3):524–534. [PubMed: 19176699] 
99. Kelly KJ, Williams WW, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-
Ramos WW, Bonventre JV. Intercellular adhesion molecule-1-deficient mice are protected against 
ischemic renal injury. Journal of Clinical Investigation. 1996; 97(4):1056–63. [PubMed: 8613529] 
100. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney International. 
2004; 66(2):486–91. [PubMed: 15253694] 
101. Haug CE, Colvin RB, Delmonico FL, Auchincloss HJ, Tolkoff-Rubin N, Preffer FI, Rothlein R, 
Norris S, Scharschmidt L, Cosimi AB. A Phase I Trial Of Immunosuppression With Antiic Am-1 
(Cd54) mAb In Renal Allograft Recipients. Transplantation. 1993; 55(4):766–772. [PubMed: 
8097341] 
102. Salmela K, Wramner L, Ekberg H, Hauser I, Bentdal O, Lins LE, Isoniemi H, Bäckman L, 
Persson N, Neumayer HH, Jørgensen PF, Spieker C, Hendry B, Nicholls A, Kirste G, Hasche G. 
A Randomized Multicenter Trial of the Anti-Icam-1 Monoclonal Antibody (Enlimomab) for the 
Prevention of Acute Rejection and Delayed Onset of Graft Function in Cadaveric Renal 
Transplantation: A Report of the European Anti-ICAM-1 Renal Transplant Study Group. 
Transplantation. 1999; 67(5):729–736. [PubMed: 10096530] 
103. Enestrom S, Druid H, Rammer L. Fibrin deposition in the kidney in post-ischaemic renal damage. 
British Journal of Experimental Pathology. 1988; 69:387–394. [PubMed: 3291926] 
Basile and Yoder Page 16
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
104. Matsuyama M, Yoshimura R, Akioka K, Okamoto M, Ushigome H, Kadotani Y, Nakatani T, 
Yoshimura M. Tissue factor antisense oligonucleotides prevent renal ischema reperfusion injury. 
Tranplantation. 2003; 76:786–791.
105. Gupta A, Williams MD, Macias WL, Molitoris B, Grinnell B. Activated protein C and acute 
kidney injury: Selective Targeting of PAR-1. Current Drug Targets. 2009; 10:1212–26. 
[PubMed: 19715537] 
106. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, 
Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and Safety of Recombinant Human 
Activated Protein C for Severe Sepsis. New England Journal of Medicine. 2001; 344(10):699–
709. [PubMed: 11236773] 
107. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall 
JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias 
WL, Vangerow B, Williams MD. Drotrecogin Alfa (Activated) in Adults with Septic Shock. 
New England Journal of Medicine. 2012; 366(22):2055–2064. [PubMed: 22616830] 
108. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in 
G2/M mediates kidney fibrosis after injury. Nat Med. 2010; 16(5):535–543. [PubMed: 
20436483] 
109. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a 
springboard for progression in chronic kidney disease. American Journal of Physiology - Renal 
Physiology. 2010; 298(5):F1078–F1094. [PubMed: 20200097] 
110. Zager RA, Johnson ACM. Renal ischemia-reperfusion injury upregulates histone-modifying 
enzyme systems and alters histone expression at proinflammatory/profibrotic genes. American 
Journal of Physiology - Renal Physiology. 2009; 296(5):F1032–F1041. [PubMed: 19261745] 
111. Kim J, Seok YM, Jung KJ, Park KM. Reactive oxygen species/oxidative stress contributes to 
progression of kidney fibrosis following transient ischemic injury in mice. American Journal of 
Physiology - Renal Physiology. 2009; 297(2):F461–F470. [PubMed: 19458120] 
112. Basile DP, Donohoe DL, Roethe K, Osborn JL. Renal ischemic injury results in permanent 
damage to peritubular capillaries and influences long-term function. American Journal of 
Physiology. 2001; 281(10):F887–F899. [PubMed: 11592947] 
113. Basile DP, Donohoe DL, Roethe K, Mattson DL. Chronic renal hypoxia following ischemia/
reperfusion injury: Effects of L-Arginine on hypoxia and secondary damage. Am J Physiol Renal 
Physiol. 2003; 284:F338–348. [PubMed: 12388385] 
114. Horbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, Sutton TA. Acute and chronic 
microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal 
Physiol. 2007; 293(3):F688–695. [PubMed: 17626153] 
115. Kwon O, Hong SM, Sutton TA, Temm CJ. Preservation of peritubular capillary endothelial 
integrity and increasing pericytes may be critical to recovery from postischemic acute kidney 
injury. Am J Physiol Renal Physiol. 2008; 295(2):F351–359. [PubMed: 18562634] 
116. Steegh FMEG, Gelens MACJ, Nieman FHM, van Hooff JP, Cleutjens JPM, van Suylen RJ, 
Daemen MJAP, van Heurn ELW, Christiaans MHL, Peutz-Kootstra CJ. Early Loss of Peritubular 
Capillaries after Kidney Transplantation. Journal of the American Society of Nephrology. 2011; 
22(6):1024–1029. [PubMed: 21566051] 
117. Basile DP. The endothelial cell in ischemic acute kidney injury: implications for acute and 
chronic function. Kidney International. 2007; 72:151–156. [PubMed: 17495858] 
118. Basile DP. Rarefaction of peritubular capillaries following ischemic acute renal failure: a 
potential factor predisposing progressive nephropathy. Current Opinion in Nephrology and 
Hypertension. 2004; 13:1–13. [PubMed: 15090853] 
119. Norman J, Fine LG. Intrarenal oxygenation in chronic renal failure. Clinical & Experimental 
Pharmacology & Physiology. 2006; 133:989–996. [PubMed: 17002678] 
120. Pechman KR, De Miguel C, Lund H, Leonard EC, Basile DP, Mattson DL. Recovery from renal 
ischemia-reperfusion injury is associated with altered renal hemodynamics, blunted pressure 
natriuresis, and sodium-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol. 2009; 
297(5):R1358–1363. [PubMed: 19710386] 
Basile and Yoder Page 17
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
121. Spurgeon-Pechman KR, Donohoe DL, Mattson DL, Lund H, James L, Basile DP. Recovery from 
acute renal failure predisposes hypertension and secondary renal disease in response to elevated 
sodium. Am J Physiol Renal Physiol. 2007; 293:F269–278. [PubMed: 17507599] 
122. Basile DP, Friedrich JL, Spahic J, Knipe NL, Mang HE, Leonard EC, Ashtiyani SC, Bacallao RL, 
Molitoris BA, Sutton TA. Impaired endothelial proliferation and mesenchymal transition 
contribute to vascular rarefaction following acute kidney injury. American Journal of Physiology 
- Renal Physiology. 2011; 300:F721–33. [PubMed: 21123492] 
123. Leonard EC, Friderich J, Basile DP. VEGF-121 preserves renal microvessel structure and 
ameliorates secondary renal disease following acute kidney injury. Am J Physiol-Renal Physiol. 
2008; 295:F1648–57. [PubMed: 18799550] 
124. Lee HT, Park SW, Kim M, D'Agati VD. Acute kidney injury after hepatic ischemia and 
reperfusion injury in mice. Lab Invest. 2008; 89(2):196–208. [PubMed: 19079326] 
125. Kida Y, Ieronimakis N, Schrimpf C, Reyes M, Duffield JS. EphrinB2 Reverse Signaling Protects 
against Capillary Rarefaction and Fibrosis after Kidney Injury. Journal of the American Society 
of Nephrology. 2013; 24(4):559–572. [PubMed: 23492730] 
126. Basile DP, Rovak JM, Martin DR, Hammerman MR. Increased transforming growth factor-β 
expression in regenerating rat renal tubules following ischemic injury. American Journal of 
Physiology. 1996; 270:F500–F509. Renal Fluid Electrolyte Physiol. 39. [PubMed: 8780254] 
127. Spurgeon KS, Donohoe DL, Basile DP. Transforming growth factor-β in acute renal failure: 
receptor expression, influence in cell proliferation, cellularity and vascularization after recovery 
from injury. Am J Physiol Renal Physiol. 2005; 288:F568–F577. [PubMed: 15536165] 
128. Basile DP, Fredrich K, Weihrauch DW, Hattan N, Chilian WM. Angiostatin and matrix 
metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol. 
2004; 286:F893–F902. [PubMed: 15075185] 
129. Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR. Renal ischemia reperfusion 
inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol 
Renal Physiol. 2008; 294
130. Kanellis J, Paizis K, Cox AJ, Stacker SA, Gilbert RE, Cooper ME, Power DA. Renal ischemia-
reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. 
Kidney International. 2002; 61(5):1696–706. [PubMed: 11967019] 
131. Johnson RJ, Schreiner GF. Hypothesis: the role of acquired tubulointerstitial disease in the 
pathogenesis of salt-dependent hypertension. Kidney International. 1997; 52(5):1169–79. 
[PubMed: 9350640] 
132. Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, Johnson 
RJ, Schreiner GF. Vascular endothelial growth factor (VEGF121) protects rats from renal 
infarction in thrombotic microangiopathy. Kidney International. 2001; 60(4):1297–308. 
[PubMed: 11576344] 
133. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the 
remnant kidney model: II. Vascular endothelial growth factor administration reduces renal 
fibrosis and stabilizes renal function. Journal of the American Society of Nephrology. 2001; 
12(7):1448–57. [PubMed: 11423573] 
134. Jung YJ, Kim DH, Lee AS, Lee S, Kang KP, Lee SY, Jang KY, Sung MJ, Park SK, Kim W. 
Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-
induced acute kidney injury. American Journal of Physiology - Renal Physiology. 2009; 
297(4):F952–F960. [PubMed: 19656917] 
135. Zhang B, Chen N, Shi W, Wang W, Shi H, Yu H. Peritubular Capillary Loss Is Ameliorated by 
Ramipril or Valsartan Treatment. Microcirculation. 2008; 15(4):337–348. [PubMed: 18464162] 
136. Long D, Mu W, Price K, Roncal C, Schreiner GF, Woolf AS, Johnson R. Vascular endothelial 
growth factor administration does not improve microvascular disease in the salt-dependent phase 
of post angiotensin II hypertension. Am J Physiol. 2006; 291:F1248–54.
137. Chade AR, Kelsen S. Reversal of renal dysfunction by targeted administration of VEGF into the 
stenotic kidney: a novel potential therapeutic approach. American Journal of Physiology - Renal 
Physiology. 2012; 302(10):F1342–F1350. [PubMed: 22357917] 
Basile and Yoder Page 18
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
138. Freeburg PB, Abrahamson DR. Hypoxia-Inducible Factors and Kidney Vascular Development. 
Journal of the American Society of Nephrology. 2003; 14(11):2723–2730. [PubMed: 14569081] 
139. Nyengaard J, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular 
capillary number and sizes. Diabetologia. 1993; 36(3):189–194. [PubMed: 8462766] 
140. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, 
Floege Jr. VEGF165 mediates glomerular endothelial repair. The Journal of Clinical 
Investigation. 1999; 104(7):913–923. [PubMed: 10510332] 
141. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, Johnson RJ. 
A new model of renal microvascular endothelial injury. Kidney International. 1997; 52(1):182–
94. [PubMed: 9211361] 
142. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn A, Claffey K, Reilly M, Couser W, Alpers C, 
Johnson R. Participation of glomerular endothelial cells in the capillary repair of 
glomerulonephritis. Am J Pathol. 1995; 147(6):1715–1727. [PubMed: 7495296] 
143. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, 
Couser WG, Johnson RJ. Glomerular cell proliferation and PDGF expression precede 
glomerulosclerosis in the remnant kidney model. Kidney Int. 1992; 41(2):297–309. [PubMed: 
1313122] 
144. Hohenstein B, Kuo MC, Addabbo F, Yasuda K, Ratliff B, Schwarzenberger C, Eckardt KU, 
Hugo CPM, Goligorsky MS. Enhanced progenitor cell recruitment and endothelial repair after 
selective endothelial injury of the mouse kidney. American Journal of Physiology - Renal 
Physiology. 2010; 298(6):F1504–F1514. [PubMed: 20237239] 
145. Basile DP, Friedrich JL, Spahic J, Knipe NL, Mang HE, Leonard EC, Ashtiyani SC, Bacallao RL, 
Molitoris BA, Sutton TA. Impaired endothelial proliferation and mesenchymal transition 
contribute to vascular rarefaction following acute kidney injury. American Journal of Physiology 
- Renal Physiology. 2011
146. Lin S, Chang F, Schrimpf C, Chen Y, Wu C, Wu V, Chiang W, Kuhnert F, Kuo C, Chen Y, Wu 
K, Tsai T, duffield J. Targetting endothelium pericyte cross talk by inhibiting VEGF receptor 
signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol. 2011; 178:911–
23. [PubMed: 21281822] 
147. Schrimpf C, Xin C, Campanholle G, Gill S, Stallcup W, Lin S, David G, Gharib S, Humphreys 
BD, Duffield JS. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. 
Journal of the American Society of Nephrology. 2012 In press. 
148. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman 
G, Isner JM. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science. 1997; 
275(5302):964–966. [PubMed: 9020076] 
149. Kogler G, Critser P, Trapp T, Yoder M. Future of cord blood for non-oncology uses. Bone 
Marrow Transplant. 2009; 44(10):683–697. [PubMed: 19802027] 
150. Patschan D, Patschan S, Muller GA. Endothelial Progenitor Cells in Acute Ischemic Kidney 
Injury: Strategies for Increasing the Cells' Renoprotective Competence. International Journal of 
Nephrology. 2011; 2011
151. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, 
Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/
progenitor cell principals. Blood. 2007; 109(5):1801–1809. [PubMed: 17053059] 
152. Asahara T, Kawamoto A, Masuda H. Concise Review: Circulating Endothelial Progenitor Cells 
for Vascular Medicine. Stem Cells. 2011; 29(11):1650–1655. [PubMed: 21948649] 
153. Rookmaaker MB, Verhaar MC, van Zonneveld AJ, Rabelink TJ. Progenitor cells in the kidney: 
biology and therapeutic perspectives. Kidney International. 2004; 66(2):518–22. [PubMed: 
15253701] 
154. Li J, Deane JA, Campanale NV, Bertram JF, Ricardo SD. Blockade of p38 Mitogen-Activated 
Protein Kinase and TGF-beta/Smad Signaling Pathways Rescues Bone Marrow–Derived 
Peritubular Capillary Endothelial Cells in Adriamycin-Induced Nephrosis. Journal of the 
American Society of Nephrology. 2006; 17(10):2799–2811. [PubMed: 16959826] 
155. Duffield JS, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, Bonventre JV. 
Restoration of tubular epithelial cells during repair of the postischemic kidney occurs 
Basile and Yoder Page 19
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
independently of bone marrow-derived stem cells. Journal of Clinical Investigation. 2005; 
115(7):1743–55. see comment. [PubMed: 16007251] 
156. Yoder MC. Defining human endothelial progenitor cells. Journal of Thrombosis and Haemostasis. 
2009; 7(s1):49–52. [PubMed: 19630767] 
157. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, 
Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary 
Transplantation of Progenitor Cells after Myocardial Infarction. New England Journal of 
Medicine. 2006; 355(12):1222–1232. [PubMed: 16990385] 
158. Napoli C, Hayashi T, Cacciatore F, Casamassimi A, Casini C, Al-Omran M, Ignarro LJ. 
Endothelial progenitor cells as therapeutic agents in the microcirculation: An update. 
Atherosclerosis. 2010; 215(1):9–22. [PubMed: 21126740] 
159. Rehman J, Li J, Orschell CM, March KL. Peripheral Blood Endothelial Progenitor Cells Are 
Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors. Circulation. 
2003; 107(8):1164–1169. [PubMed: 12615796] 
160. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner 
JM. Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal 
Vasculogenesis in Physiological and Pathological Neovascularization. Circulation Research. 
1999; 85(3):221–228. [PubMed: 10436164] 
161. Yasuda K, Park HC, Ratliff B, Addabbo F, Hatzopoulos AK, Chander P, Goligorsky MS. 
Adriamycin Nephropathy: A Failure of Endothelial Progenitor Cell-Induced Repair. Am J Pathol. 
2010; 176(4):1685–1695. [PubMed: 20167859] 
162. Patschan D, Krupincza K, Patschan S, Zhang Z, Hamby C, Goligorsky MS. Dynamics of 
mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation 
by ischemic preconditioning. American Journal of Physiology - Renal Physiology. 2006; 
291(1):F176–F185. [PubMed: 16478972] 
163. Schwarz TM, Leicht SF, Radic T, Rodriguez-Araboalaza I, Hermann PC, Berger F, Saif J, Becker 
W, Ellwart JW, Aicher A, Heeschen C. Vascular Incorporation of Endothelial Colony-Forming 
Cells Is Essential for Functional Recovery of Murine Ischemic Tissue Following Cell Therapy. 
Arteriosclerosis, Thrombosis, and Vascular Biology. 2011; 32(2):e13–e21. epub ahead of print. 
164. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel 
paradigms for defining endothelial progenitor cells. Blood. 2005; 106(5):1525–31. [PubMed: 
15905185] 
165. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang 
HK, Oh BH, Park YB, Kim HS. Synergistic Neovascularization by Mixed Transplantation of 
Early Endothelial Progenitor Cells and Late Outgrowth Endothelial Cells. Circulation. 2005; 
112(11):1618–1627. [PubMed: 16145003] 
166. Yoder MC. Is Endothelium the Origin of Endothelial Progenitor Cells? Arteriosclerosis, 
Thrombosis, and Vascular Biology. 2010; 30(6):1094–1103.
167. Basile DP, Zeng P, Friedrich JL, Leonard E, Yoder MC. Low proliferative potential and impaired 
angiogenesis of cultured rat kidney endothelial cells. Microcirculation. 2012; 19:598–609. 
[PubMed: 22612333] 
Basile and Yoder Page 20
Cardiovasc Hematol Disord Drug Targets. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. 
Summary of tubular and vascular events in the initiation and recovery from ischemic AKI. 
Top Panel, Time line of loss of GFR in response to renal ischemia shown in relation to the 
corresponding phases (Initiation, Extension, Maintenance, and Recovery) described by 
Molitoris and Sutton [37]. Early reduction of GFR in the initiation phase is mediated 
initially be changes in vascular tone. Arrows and lines show the anticipated effects of 
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endothelial targeted treatments. Treatment A1 (purple dashed line) indicates preservation of 
function when treatments effecting tone, (e.g., supplementation of NO or vasoconstrictor 
antagonists) are provided during initiation, while Treatment A2 (purple dotted line) shows a 
lack of efficacy of these treatments when provided during the extension phase. Similarly, 
treatments that disrupt endothelial leukocyte interactions are effective when provided during 
initiation (B1, green dashed line). The effect of anti-leukocyte during the extension phase is 
not yet clear, but is predicted to have potential beneficial effects (B2?, green dotted line). 
Capillary density is indicated by the red lines: rarefaction progresses in the extension and 
maintenance phases and does not resolve; pro-vasculogenic treatments preserve capillary 
density when provided during the extension phase (C1), but lack effect at later times (C2). 
Bottom Panel summarizes altered cellular and molecular events associated with the phases 
of injury in both the tubular and vascular compartments, with an emphasis on events linked 
with vascular perfusion. The photomicrograph in “normal” state illustrates intact vascular 
density in control rats, while capillary rarefaction is observed in the post-recovery phase 
(photomicrographs from [112]). Loss of microvasculature occurs, in part, via endothelial 
mesenchymal transition (EndoMT) which can be observed in the extension and maintenance 
phase. EndoMT is illustrated by co-localizing S100-A4 (red) in capillary EC (blue) 
(highlighted by thin black arrow, from citation [122].
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